Candidates

 
 
 
  •  
    MORE
  • PARP Inhibitors

    IMPACT has discovered two series of novel PARP Inhibitorswith more than 60 novel compounds that are many folds more potent than AZD2281

     
    MORE
  • Hedgehog Pathway Inhibitors

    IMPACT has discovered three series of novel Hedgehog pathway inhibitors and has identified more than 10 compounds that are 10-100 folds more potent than the approved Hedgehog inhibitor GDC-044

     
    MORE
  • Microtubule Inhibitor

    IMPACT has discovered two series of novel small molecular microtubule inhibitors, and selected IMP3138 as a clinical candidate for further development.

     
    MORE

About Impact

Impact Therapeutics is a privately held clinical-stage biopharmaceutical company incorporated in Nanjing, China, dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality.

MORE

Join us

IMPACT regards employees as the most valuable asset of the company, willing to absorb all outstanding and potential talents, and provides a broad career development space for each employee.

MORE